Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Mid-range Performer

1961.6000 -28.20 (-1.42%)

NSE Aug 14, 2025 15:31 PM

Volume: 859.1K

Lupin Ltd.

16 Dec 2024

1961.60

-1.42%

Lupin (BUY): Reduction in in-licence portfolio to increase margins

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's domestic region in-licence portfolio fell from 15% in Q2FY24 to 12% in Q2FY25 and is expected to reduce further to ~10% by FY26

Lupin Ltd. has an average target of 2315.43 from 7 brokers.